Background/Aims: Bleeding complications after percutaneous coronary intervention (PCI) are strongly associated with adverse patient outcomes. However, there are no specific guidelines for the predictors and management of antiplatelet-related bleeding complications in Chinese elderly patients with acute coronary syndrome (ACS). Methods: A retrospective analysis of 237 consecutive patients (aged ≥ 75 years) with ACS who had undergone successful PCI from January 2010 to December 2016 was performed to identify predictors and management of antiplateletrelated bleeding complications. Multivariate logistic regression analysis was conducted to investigate independent predictors of antiplatelet-related bleeding complications. We defined antiplatelet-related bleeding complications as first hospitalization received long-term oral antiplatelet therapy and required hospitalization, including gastrointestinal and intracranial bleedings. Results: After multivariable adjustment, independent risk predictors of antiplateletrelated bleeding complications included female gender (odds ratio [OR]: 2.96; 95% confidence interval [CI]: 1.98 to 4.15; P = 0.011), body mass index (OR: 1.54; 95% CI: 1.06 to 1.94; P = 0.034), previous history of bleeding (OR: 4.03; 95% CI: 1.84 to 6.12; P = 0.004), fasting blood glucose (OR: 2.79; 95% CI: 1.23 to 4.46; P = 0.025), and chronic total occlusion lesion (OR: 4.69; 95% CI: 2.19 to 7.93; P = 0.007). Of 46 patients with antiplatelet-related bleeding complications, 54.3% were treated short-term dual antiplatelet therapy (DAPT) cessation (0-7 days) and 45.7% underwent long-term DAPT cessation (>7 days). Among these, 14 patients presented major adverse cardiac and cerebrovascular events (MACCE), whereas no re-bleeding happened over all available follow-up. The incidence of MACCE was not significantly different between the two groups one year after PCI (36.0% for short-term DAPT cessation versus 23.8% for longterm DAPT cessation, P = 0.522). Conclusion: For elderly patients with ACS, multiple factors were likely to contribute to antiplatelet-related bleeding complications, especially previous history of bleeding and chronic total occlusion lesion. Better individualized, tailored and riskadjusted antiplatelet therapy after PCI is urgently needed in this high-risk population.
Introduction
Elderly people represent an increasing proportion of the acute coronary syndrome (ACS) population worldwide, accounting for up to a third of patients [1] , and a trend also observed in Chinese elderly adults [2] . In parallel, these frail patients have frequent comorbidities, including age-related changes in cardiovascular structure and function, other organ systems dysfunction (including the kidneys, liver, skeletal muscle, and brain), and multiple medications received, exposing them to an increased risk of iatrogenic complications [3, 4] . As a result, current evidence-based practice guidelines suffer inherent gaps in providing recommendations for managing older adults with ACS, the majority of whom would not have been eligible for participation in most of the major randomized clinical trials [3] . Hence, there are currently no specific guidelines concerning the management of antiplatelet therapy for ACS in elderly patients, especially for Chinese elderly adults (≥ 75 years of age) [3, 5, 6] .
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor reduces ischaemic recurrences in patients with ACS treated with percutaneous coronary intervention (PCI), but increases bleeding [7] . In this regard, approximately half of the major bleeds in patients aged 75 years or older are gastrointestinal bleeding (GIB) [8] , an uncommon but devastating complication of regular antiplatelet use is intracerebral haemorrhage (ICH) [9] . An increasing number of data indicates that the Asian population that present with ACS or undergo PCI display highly variable risk profiles for bleeding when compared with the Western population [10] . Of note, the identification of distinct predictors for antiplateletrelated bleeding complications may provide opportunities to further tailor post-PCI care for those at high bleeding risk, yet studies dedicated to the risk predictors of antiplateletrelated bleeding complications after PCI in Chinese elderly people are rarely done [3, 6, 11] . Furthermore, bleeding is strongly associated with the occurrence of mortality within one year after bleeding complications [12] . Timely cessation of antiplatelet therapy is a critical component of the successful management of antiplatelet-related bleeding complications in patients with ACS [13] . However, much less is known about the contemporary timing relations between physician-guided DAPT cessation and subsequent major adverse cardiac and cerebrovascular events (MACCE) in Chinese elderly patients with ACS.
Our aim of this study was to identify risk predictors of antiplatelet-related bleeding complications (GIB or ICH) for ACS in elderly patients, assess the management associated with these patients, and synthesize the available information of our clinical experience to provide clinicians with a new interpreting to appropriate antiplatelet strategies.
Materials and Methods

Subjects
This study was a single-center retrospective study involved consecutive patients who had undergone successful PCI referred to the First Affiliated Hospital of Chengdu Medical College from January 2010 to December 2016. The inclusion criteria for the study were as follows: aged ≥ 75 years old; fulfill the ACS criteria [13, 14] ; successful PCI in at least one major coronary artery; received standard antithrombotic treatment for the PCI procedure [7] ; and angiographically documented PCI. Patients were excluded if they 
Data Collection
Medical chart reviews undertaken by the research nurse and the self-administered questionnaires were used to collect participants' medical history, health behaviors, and index ACS characteristics; clinical risk profile; and medical management data. Information on demographics (age and sex), comorbidities, lifestyle variables (smoking status, alcohol consumption, and body mass index), and biological data was extracted from the database or medical chart reviews.
For the present study, the SYNTAX score for each angiogram was assessed by two experienced interventional cardiologists blinded to treatment assignment and clinical outcomes [15] . The GRACE score calculator was applied on all selected patients for the weighing of ischemic risk [16] . The CRUSADE bleeding risk score was calculated for each patient by assigning certain number of points for weighted integers of each of the eight independent predictors (gender, diabetes mellitus, peripheral arterial disease, heart rate, systolic blood pressure, heart failure, haematocrit and creatinine clearance) of in-hospital bleeding events [17] .
Definitions
The primary bleeding complications of interest after PCI were classified as GIB or ICH. GIB was defined as overt or occult bleeding within the gastrointestinal tract that occurred during a period of antiplatelet therapy [18] . An overt bleed was classified as melena, hematochezia, hematemesis, and coffee ground emesis. An occult bleed was defined as an acute drop in hemoglobin with positive fecal occult blood test and negative upper and lower endoscopies. ICH was diagnosed according to the World Health Organization criteria [19] , and confirmed by head computed tomography (CT) or magnetic resonance imaging (MRI). Major bleeding was diagnosed according to the standardized bleeding definitions for cardiovascular clinical trials by the American Bleeding Academic Research Consortium, and types 3 and 4 were defined as major bleeding [20] . Antiplatelet-related bleeding complications were defined as first hospitalization received long-term oral antiplatelet therapy and required hospitalization, including gastrointestinal and intracranial bleedings [21] . DAPT cessation was defined as cessation of antiplatelet treatment due to bleeding [22] . Once hemostasis had been assured and no continuing or recurrent hemorrhage, DAPT cessation did not preclude that low or standardized dose of clopidogrel monotherapy was timely restarted. Additionally, DAPT cessation did not preclude patients from subsequently resuming DAPT after this time interval, including length of DAPT >7 days. MACCE were defined as the composite of cardiac death, definite or probable stent thrombosis, spontaneous myocardial infarction, clinically indicated target lesion revascularisation or nonfatal ischemic stroke [22] [23] [24] . Re-bleeding was defined as further hematemesis and/or melena and/or hypovolemic shock after first endoscopy [25] , or defined as a change of at least four points in the National Institutes Health stroke scale (NIHSS) score within the first 72 h after hospital admission together with an increase of intracranial bleeding on brain imaging [26] .
DAPT cessation for subjects with antiplatelet-related bleeding complications
All the patients with antiplatelet-related bleeding complications had a DAPT cessation after initial bleeding, and further classified by duration of cessation as either short-term (0-7 days), or long-term (> 7 days). In addition, follow-up by standardized telephone interview or outpatient clinical visits were scheduled at 30 days, 3 months, 6 months, and 12 months after DAPT cessation. Of the initial 53 patients Cellular Physiology and Biochemistry
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with antiplatelet-related bleeding complications, 7 were ineligible for one year follow-up, including 4 patients in short-term DAPT cessation group and 3 patients in long-term DAPT cessation group. 3 patients were lost to phone contact, 2 patients denied verbal consent, and 2 patients failed to complete all required information. Eventually, a total of 46 patients with antiplatelet-related bleeding complications treated by DAPT cessation were followed. During the telephone interview, the site staff obtained information regarding major adverse events and deaths. All major adverse events were adjudicated by an independent clinical events committee blinded to treatment assignment.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD). Categorical variables were expressed as a percentage. Continuous variables were compared using Student's t-test, while categorical variables were compared using chi-square tests. Since this study was retrospective design and sample size was limited due to the availability of samples, we estimated the power of our study. However, 1:3 (or greater) case:control matching was used to maximize statistical power. Univariable logistic regression analysis was used to estimate the effect of various variables on the hazard of bleeding complications. Multivariate logistic regression analysis was then performed to identify independent predictors of bleeding complications. Variables in these models were selected based on univariate p-values of < 0.05 and overall clinical significance. Odds ratios (ORs) and their 95% confidence intervals (CIs) along with corresponding p values were presented. Kaplan-Meier survival curves were constructed for MACCE occurrence in patients treated with short-term or long-term DAPT cessation and compared with the log-rank test. All statistical analyses were conducted using STATA (version 12.0) and SPSS (version 22.0). Two-sided P < 0.05 was considered statistically significant.
Results
Characteristics of study patients
Baseline characteristics of the initial 237 patients studied are shown in Table  1 . Compared with patients without bleeding, those with bleeding were significantly associated with the following parameters: greater proportion of female genger, lower values of body mass index (BMI), lower presence of non-ST segment elevation myocardial infarction (NSTEMI), higher levels of systolic blood pressure, fasting blood glucose (FBG), length of stent, GRACE score, CRUSADE score, and the prevalence of smoking, alcohol consumption, and the presence of STsegment elevation myocardial infarction (STEMI), diabetes, hypertension, dyslipidemia, previous history of bleeding, and chronic total occlusion (CTO) lesion. 
Multivariate analysis
The associations of patients' baseline characteristics with bleeding complications, estimated by univariable logistic regression analysis, are presented in Table 2 . The results of multivariate logistic regression analysis on bleeding complications after PCI are shown in Fig. 1 . On multivariate analysis, female gender (OR: 2.96; 95% CI: 1.98 to 4.15; P = 0.011), BMI (OR: 1.54; 95% CI: 1.06 to 1.94; P = 0.034), previous history of bleeding (OR: 4.03; 95% CI: 1.84 to 6.12; P = 0.004), FBG (OR: 2.79; 95% CI: 1.23 to 4.46; P = 0.025), and CTO lesion (OR: 4.69; 95% CI: 2.19 to 7.93; P = 0.007) were independent predictors of bleeding complications (Fig. 1) .
Characteristics and clinical outcomes of DAPT cessation
Characteristics and clinical outcomes of short-term or long-term DAPT cessation for patients with antiplatelet-related bleeding complications are presented in Table 3 . Of 46 patients with antiplatelet-related bleeding complications, 54.3% were treated shortterm DAPT cessation and 45.7% underwent long-term DAPT cessation. Among these, 14 patients presented MACCE, whereas no re-bleeding happened over all available followup. The incidence of MACCE was not significantly different between the two groups one year after PCI (36.0% for short-term DAPT cessation versus 23.8% for longterm DAPT cessation, P = 0.522) ( Table  3) . Kaplan-Meier survival curves and cumulative event rates for MACCE in patients with short-term DAPT cessation or long-term DAPT cessation are shown in Fig. 2 . There was no significant difference in MACCE rate between the groups with short-term DAPT cessation or long-term DAPT cessation (log-rank P = 0.481 [ Fig.  2] ). Not surprisingly, two interesting cases illustrating the judicious tailoring of antiplatelet therapy were described in Supplemental information (for all supplementary material see www.karger. com/doi/10.1159/000494543). 
Discussion
This study reports the predictors and treatment experience of antiplatelet-related bleeding complications after PCI for ACS in elderly patients in a single center. Furthermore, our findings show that patients who had physician-guided long-term DAPT cessation did not have an obviously increased rate of MACCE events, compared with those on short-term DAPT cessation.
These results permit several conclusions. First, bleeding complications are associated with adverse outcomes after PCI [12] , risk stratification is important for such patients to enable an appropriate therapeutic approach for each individual case. In contemporary primary PCI, the occurrence of access site bleeds is rare even in high risk population [27, 28] . In fact, access-related bleedings (i.e., femoral, or radial artery) were not associated with an excess in 30 day mortality, but the rest of the bleeds (i.e., GIB or ICH) were [27, 28] . Therefore, emphasis, among those PCI patients with ACS, needs to now focus on how to reduce non-access site bleeds.
Antithrombotic drugs are associated with a clinically significant risk of GIB or ICH [5] . Regarding the independent predictors of bleeding complications on multivariate analysis (female, low BMI, previous history of bleeding, and FBG), our results are mostly consistent with those of previous studies [17, 29, . In addition to these common factors, PCI for CTO lesions is also independent predictor of bleeding complications in our study, perhaps on the basis of the advent of newly developed devices and techniques, sufficient procedural success and acceptable complication rates have been achieved [31] . It should be noted, however, that previous studies did not focused on the older adult. Accordingly, age over 75 years was a mandatory inclusion criterion in our study. Second, compared with those on short-term DAPT cessation, patients who had physician-guided long-term DAPT cessation did not have an obviously increased rate of MACCE events. These results are consistent with those of Mehran et al. [22] who found that cardiac events after DAPT cessation depend on the clinical circumstance and reason for cessation and attenuates over time; yet the authors did not focus on Chinese population. Nonetheless, in a meta-analysis of the duration of DAPT in patients treated with secondgeneration drug-eluting stents, major bleeding was reduced by shorter DAPT (OR: 0.60; 95% CI: 0.42 to 0.96), emphasizing the need for an individualized approach to balance the competing risks of bleeding and myocardial infarction when deciding on the optimal DAPT duration for each patient [32] . Third, in general, management of antiplatelet-related bleeding complications includes identification and treatment of the bleeding source, haemostatic intervention (manual, endoscopic, and surgical), discontinuation of antithrombotic drugs (partial or complete), replacement therapy, and antidotes if available, depending on bleeding severity and risk of ischaemic recurrence [5, 33, 34] . Transfusions are recommended in haemodynamically unstable patients or with haematocrit < 25% or haemoglobin < 7 g/dL [5, 35] . Well-established scores of ischemic and bleeding risk, such as GRACE and CRUSADE, are imperative for sound decision-making regarding drug cessation or continuation [36, 37] . Moreover, knowledge of the mechanism of action, half-life and elimination route of the antiplatelet agent, as well as timing of last administration and kidney function, are important for optimal management [5] .
Management of GIB in the elderly
Antiplatelet agents increase the risk of major bleeding complications after PCI, among which GIB is the commonest manifestation [38] . The association between GIB and antiplatelet agents is well recognized [39] . The current state-of-the-art management of GIB also should consider the following important approaches. Firstly, Aspirin is a cyclooxygenase (COX) inhibitor that inhibits both COX-1 and COX-2 and causes irreversible inhibition of platelet function [40] . The time required to recover adequate platelet function after aspirin use is 7 to 10 days. The thienopyridine agents, clopidogrel, prasugrel, and ticagrelor, inhibit the P2Y 12 receptor on the platelet to inhibit platelet aggregation. Inhibition is irreversible for clopidogrel and prasugrel and reversible for ticagrelor [40] . The antiplatelet effect can last between 3 and 9 days depending on the agent [38] . Following ACS, regardless of whether the patient has been medically treated or undergone PCI, the most dangerous period of time to alter DAPT is in the first 90 days following the event [41] . Elective diagnostic endoscopy can safely be performed without cessation of DAPT [38] . Secondly, the European guidelines recommend a PPI with DAPT to reduce GIB events [5, 42] . With clopidogrel, PPIs with low CYPC19 inhibitory capacity (e.g. pantoprazole) are preferred [5, 42] . Thirdly, other measures include blood pressure control, avoidance, or limited use of other drugs that enhance bleeding (e.g. NSAIDs, steroids), avoidance of heavy alcohol intake [5, 42] . Fourthly, once endoscopic hemostasis has been assured, antiplatelets should be restarted; on the same day of the procedure, in most cases. In situations in which hemostasis is uncertain, discussion with the patient's cardiologist, hematologist, or gastroenterologist is important to ensure an individualized approach for each patient.
Management of ICH in the elderly
Antiplatelet therapy might slightly increase the incidence of ICH [42] . The effect of antiplatelet drugs on the outcome of ICH is uncertain [43] . Previous observational studies showed that reduced platelet activity is associated with early ICH growth, and poor functional outcome [44, 45] . Another study reported that the use of antiplatelet medication at the
onset of ICH symptoms was not associated with increased hemorrhage volume, hematoma expansion, or poor functional outcome [46] . The current state-of-the-art management of ICH also should consider the following important approaches. Firstly, platelet transfusion is used prophylactically and therapeutically in many clinical settings; however, few randomised trials have investigated its effectiveness for active bleeding disorders [47, 48] . In the findings of the PATCH trial, platelet transfusion cannot be recommended for the treatment of acute intracerebral haemorrhage in people taking antiplatelet therapy because platelet transfusion seemed to worsen their outcome [49] . Secondly, the condition of patients with ICH frequently deteriorates within the first 24 or 48 hours after symptom onset because of secondary injuries caused by hematoma expansion, intraventricular hemorrhage extension, fever, and high blood pressure [50] . Preliminary studies have suggested that therapeutic cooling may reduce perihematomal edema [51] . On the other hand, intensive blood pressure reduction is thought to reduce hematoma expansion and improve the clinical outcomes in patients with ICH. However, the therapeutic goals of blood pressure reduction in the early phase of ICH are not clearly defined. The key point to debate is whether acute blood pressure reduction results in ischemic insult to perihematomal penumbral lesions surrounding the hemorrhage [50, 52, 53] . Overall, the current evidence supports that early intensive blood pressure lowering is safe and feasible, and is associated with a modestly better functional outcome. Thirdly, hyperglycemia on admission is associated with an increased 28-day case fatality in both nondiabetic and diabetic patients with ICH [19] . Therefore, hyperglycemia should be controlled adequately, glucose level should be monitored regularly and both hyperglycemia and hypoglycemia should be avoided [19, 54] . Fourthly, after ICH, resuming antiplatelet therapy should be considered with great caution, especially after lobar bleeds that have higher recurrence rates than deep cerebral bleeds [5, 42] . There are several possible explanations for our findings. First, there is a wide consensus that antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence [55] . Current guidelines advocate a DAPT with aspirin and clopidogrel for up to 12 months [33] . It is important to emphasize that this intensification of treatment is associated with an increased risk of bleeding. In addition, evidence has been accumulating for a strong association of bleeding with subsequent mortality, the causes of which are thought to be multifactorial [56] . Various mechanisms can explain this association: bleeding can directly lead to death (in case of severe hemorrhage or intracranial bleeding, for example), prompt cessation of antithrombotic therapy and thus induce ischemic events, and coupled with medications required to treat bleeding (such as transfusion) can also affect prognosis [57] . Second, to date, there are no randomized control trials that systematically explore the timing of restarting antithrombotic drugs after bleeding complications [5, 42] . Given the risk of thrombotic events and recurrent bleeding, few studies recommends individualized timelines. Moreover, there is a pervasive lack of evidence to guide clinical decision making in older patients with cardiovascular disease, as well as a paucity of data on the impact of diagnostic and therapeutic interventions on key outcomes that are particularly important to older patients, such as quality of life, physical function, and maintenance of independence [3] . Third, physicians appropriately discontinue DAPT in patients with bleeding complications accounting for improving MACCE events after discontinuation. Additionally, one potential explanation is that patients undergoing PCI are indeed different; their levels of platelet activation, their comorbidities, and demographics all may lead to a completely different balance of risk and benefit. Fourth, the pharmacodynamic response to clopidogrel is associated with a large interindividual variability, especially in those with the lowest onclopidogrel reactivity the risk of bleeding is increased [58] . More importantly, certain studies have already suggested that Asian patients may respond differently to antithrombotic therapy in comparison with the Western population [10] . Platelet function testing is still being used in many centres and international guidelines still recommend platelet function testing in high-risk situations. However, attempts have not been made to characterize the efficacy of antiplatelet therapy using platelet function testing in our centre mainly based [4, 59] .
The main strength of our study is that it provides new insight on the options for individual risk assessment and strategies to personalize antiplatelet therapy in Chinese elderly patients with bleeding complications (GIB or ICH). Given the differing risk profiles between Chinese patients and those in the Western population [60] , we not only specifically addressed predictors of bleeding complications after PCI, but also tested interactions between DAPT cessation and cardiovascular risk. Our findings may have significant clinical implications, as individuals' characteristics and angiographic factors are all independently associated with bleeding complications after PCI, and therefore need to be considered separately for precise prediction of bleeding risk. Furthermore, these findings might provide the foundation for future evidence-based guidelines applicable to older patients, thereby enhancing patientcentered evidence-based care of older people with cardiovascular disease in China and around the world.
Limitations of our study warrant consideration. First, this was a retrospective study, residual and uncontrolled confounding might still be present. Although we performed multivariate logistic regression analysis to adjust for possible confounding variables, some selection bias might not have been completely adjusted for in our statistical model. In addition, information on comorbidities, such as smoking, alcohol consumption, hypertension, diabetes, and dyslipidemia, was self-reported by participants, which potentially can lead to error. Second, the incidence of bleeding complications after PCI was low [61, 62] , and we exclusively recruited patients with definite antiplatelet-related bleeding complications after PCI; hence, the study sample was relatively small. Third, this was a single-center study based on clinical data from our hospital database. Fourth, we were not able to assess the actual dosage of antiplatelet therapy that patients received, raising the question of whether specific dosage-related factors may have had an influence on the risk of bleeding after PCI. Thus, these findings have to be confirmed by further prospective, well-designed multicenter studies.
Conclusion
For elderly patients with ACS, multiple factors were likely to contribute to antiplateletrelated bleeding complications, especially previous history of bleeding and chronic total occlusion lesion. Better individualized, tailored and risk-adjusted antiplatelet therapy after PCI is urgently needed in this high-risk population.
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